BioAdaptives, Inc. has made a significant move in the pharmaceutical sector by entering into a Membership Interest Purchase Agreement to acquire Xycota Biosciences LLC. This acquisition, announced on November 4, 2026, is poised to enhance BioAdaptives' portfolio, particularly in the development of innovative treatments for central nervous system disorders.

The acquisition is particularly noteworthy as it aligns with the growing trend in the pharmaceutical preparations industry towards consolidation and innovation. By bringing Xycota into its fold, BioAdaptives aims to leverage Xycota's preclinical programs, which include a sub-perceptual oral psilocybin candidate for PTSD and an exosome-formulated psilocin candidate for frontotemporal dementia.

Company Background

BioAdaptives, Inc. is a Delaware corporation operating in the pharmaceutical preparations sector, specifically under the SIC code 2834. The company trades under the ticker BDPT on the OTC exchange. BioAdaptives focuses on developing innovative nutraceutical products, including its Xcellara™ and MyndSystem™ lines. The recent filing indicates the company has been active in securing its financial and operational strategies, with a series of filings leading up to this acquisition.

What the Filing Says

According to the SEC filing (accession number 0001640334-26-001712), the agreement stipulates that BioAdaptives will acquire 100% of Xycota's membership interests, making it a wholly-owned subsidiary. The filing notes, "Xycota will operate as a separate subsidiary under its existing executive and scientific leadership while the Company’s commercial nutraceutical lines continue under current Parent management." This operational separation is designed to maintain focus on both entities' core business areas.

Impact

The acquisition is expected to impact various stakeholders, including existing shareholders, employees, and customers of both BioAdaptives and Xycota. The introduction of Xycota's innovative product candidates into BioAdaptives' portfolio may enhance the company's market position and growth potential in the pharmaceutical preparations industry. However, the issuance of new convertible preferred stock to the founders of Xycota could lead to significant dilution for existing shareholders.

What's Next

The filing does not specify what happens next, but it indicates that the acquisition is subject to the satisfaction or waiver of closing conditions. Following the closing, BioAdaptives is obligated to issue new series of convertible preferred stock to Xycota's founders, which will require further actions by the Board of Directors and potential regulatory filings.